Sarah Clark is a medical affairs leader with global experience in pharma and biotech. At Novo Nordisk, she leads medical excellence and strategic scientific communication for rare disease organization, building a future-ready medical affairs department. Previously, she held senior roles at Biogen and Biogen Digital Health, advancing strategy and integrating digital and personalized approaches in neuroscience. A pharmacist with an International Executive MBA from the University of St. Gallen, Sarah brings scientific expertise and clear vision, with a focus on how to elevate medical affairs to improve patient care.

Emma is currently the Head of Global Digital Health Technology Innovation at Amgen. In her capacity she is overseeing medical excellence and the digital transformation across the organization, focusing on new ways of working through streamlining process, delivering new/enhanced systems and driving capability build and engagement.

Troels Sørensen has over 25 years of experience in the pharmaceutical industry with a unique broad profile across gene therapy, biologic, and small molecule specialty care, executing customer-facing and leadership roles in Research, Clinical Operations, Medical Affairs, Sales, Marketing and Commercial Asset/Portfolio evaluation.

His passion is equitable population health attainment through the integration of public and private sectors of health systems by the development of common language, measures, and goals along the tactic to impact continuum. He devised the Target Population Output (TPO) measurement, a common tool for public and private stakeholders to align population health and business goals. TPOs have been implemented and refined since 2020. In 2023 TPOs were introduced publicly in the context of the Harvard Health System Innovation Lab’s Strategic Public Private Partnership (SPPP) framework, and in 2024 this was presented, by Harvard, at the World Economic Forum, Davos, in a session hosted by them, Novartis and Novo Nordisk.

As Global Head of Clinical Practice at Boehringer-Ingelheim, Troels leads Global Medical Affairs Partnerships, Implementation Science and TPO teams. Troels continues to work on practical and pragmatic solutions for alignment and goal setting within the pharmaceutical industry to facilitate partnership and integration with health systems.

Based in Basel, Switzerland, Troels, has worked for several pharmaceutical companies including Roche, Johnson & Johnson, UCB, AstraZeneca, Takeda, and Novartis. He is an alumnus of the European Schools System, Oxford University, the British Medical Research Councils’ National Institute for Medical Research (now The Francis Crick Institute) and Warwick Business School.

After completing his medical studies and a Master’s Degree in Pharmacology in South Africa, Danie spent 3 years working in a primary care setting including his own private practice. He joined the pharmaceutical industry in 1993, worked in Medical Affairs, Marketing, Pharmacovigilance and Clinical Operations. He held roles of increasing responsibility and leadership, including Senior Vice President and Head of Worldwide Medical Affairs at GlaxoSmithKline. In 2019, Danie joined Kyowa Kirin International as the Executive Vice President for Medical Affairs, a role which he held until recently.

He is registered with the medical councils in the UK and South Africa and completed his MBA through Heriot Watt University and Edinburgh Business School in 2006. He is a Board Chair of the Medical Affairs Professional Society (MAPS) Board, and an affiliate member of the Association for Professional Executive Coaching and Supervision (APECS).

Following Graduation in Medicine at the Free University Berlin, Michael pursued a career in General, Cardiovascular and Surgical Oncology in Germany and the UK, gaining an MD and an FRCS.  He joined pharmaceutical industry 25 years ago and has since been in clinical development, project leadership, and commercial and medical affairs roles at country, regional and global level. To date, Michael leads the Medical Affairs Team of Novartis Oncology, Region Europe.
Throughout his industry career, Michael mainly covered specialty care areas, e.g. Oncology and Immunology. He also qualified as a Pharmaceutical Physician and as an MBA. Research interests and publications are in Oncology and Immunology as well as in general aspects concerning Medical Affairs and Medicine Development in the Industry.

Natasha Hansjee, PhD, is a global principal scientific communication director at Roche. She is also  an executive coach and a storyteller. She has over 20 years of pharmaceutical marketing experience: sales, local & global strategic product management; global product commercial strategy training; scientific communications; mentoring, coaching and facilitating - and has worked across all stages of the life cycle (early launch, launch, LoE). 

Olivia is an experienced leader working in the pharmaceutical industry for over 17 years, holding senior executive leadership positions throughout organizations of different sizes and in functions ranging from Patient Services, Medical Affairs, Marketing and Sales at local and international levels in Oncology, Rare Disease and Immunology.

She has managed products along the entire life-cycle with experience ranging from integrated evidence planning, Ph 3 go-to-market modeling through to management of loss of exclusivity .

She is a medical doctor with a Bachelor's Degree in Corporate Management and Entrepreneurship.

Also she holds a training in Healthcare System Transformation, experience as a DEI leader, and is a certified Coach.

Joris van Vugt, Senior Medical Director at Viatris, studied Health Sciences at Maastricht University in The Netherlands and holds a Master in Pharmaceutical Medicine from Hibernia College in Dublin, Ireland.  He has over 20 years of experience in Medical Affairs in local, regional and global positions at Pfizer and since 3 years at Viatris. He currently focusses on strategic scientific partnerships to address unmet global health needs, including health equity, integration of care, human resources for health and capability development of the healthcare workforce.

Ron Weathermon, PharmD, is a seasoned Medical Affairs leader with more than 25 years of experience spanning global, regional, and local roles in the pharmaceutical industry. As Head of Innovation and Scientific Excellence at Teva Global Medical Affairs, he drives the development of forward-looking medical strategies, fosters cross-functional collaboration, and champions scientific innovation and governance across the organization. Prior to joining Teva, Ron served as Global Head of Medical Affairs Governance at Novartis, where he led large-scale organizational transformations, established a global governance framework, and expanded medical field capabilities. Recognized for his ability to align scientific excellence with business strategy, he has built and developed high-performing teams, enhanced medical compliance systems, and integrated medical functions across diverse therapeutic areas—advancing both innovation and operational rigor.

SSourav is currently the Head of Global Services, Medical and Scientific Affairs at Boehringer Ingelheim. He leads the Medical and Scientific Affairs Communication services hub in the Barcelona delivery unit, supporting our Medical Affairs teams in HQ and regions execute on their scientific communication priorities across Field and digital channels at scale. He has over 18 years of experience in the industry and has held medical engagement strategy and execution roles across Life Science companies driving capability building and change at scale in complex big pharma matrix environments.

Emma is a scientist at heart, strategic leader in practise, integrating evidence to inform programme viability in drug development with a passion to involve the patient community at the earliest possible stage. Emma switched from academia to industry relatively recently, initially taking on a role as a Global Patient Engagement Lead, and is now leading a New Product Planning team assessing new targets (all modalities and all therapeutic areas!) for early-stage programmes. Prior to entering industry, Emma held various academic positions at Cardiff University lecturing on Pharmacology and culminating in the position of Reader of Neuropharmacology

Daniel Newman is an award-winning patient thought leader advancing health equity through experience. Trusted by organisations including NHS England, National Institute for Health and Care Excellence (NICE), Roche, Boehringer Ingelheim, Abbott, Insulet and The University of Oxford, Daniel ensures patient voices are embedded in research, policy and service design. 

With a professional background of 15 years in HR, progressing to Senior HR Manager level, Daniel brings expertise in organisational development, leadership, and inclusive workplace practices to his advocacy work.

A champion of inclusive engagement, Daniel develops collaborative strategies and targeted interventions to address healthcare inequities and ensure underserved communities are represented in decision-making. He contributes to healthcare forums, patient advisory boards, and international conferences, while collaborating with industry partners to shape clinical trials and working with organisations to define research priorities that reflect patient needs.

Guided by his principle of evidence-based approach, Daniel demonstrates how lived experience can drive sustainable, compassionate, and equitable healthcare, improving outcomes for marginalised communities.

An expert in physician engagement. Maria partners with pharma to create meaningful connections with HCPs. She strives to inspire authentic dialogue, shape strategy, and deliver positive change in clinical practice.

Chris Bassett is Sales Director for UK and Northern Europe at Springer Healthcare (part of the Springer Nature group).  Based in the UK, Chris started his Springer career as Commercial Partnership Manager, managing Springer’s relationships with key society and content stakeholders, such as ASCO and ASH.  In recent years, Chris has developed and now leads an expert team of educational content developers, delivering a wide range of solutions for healthcare professionals.   From in-person expert meetings and traditional print tools, through to interactive learning modules, live and on-demand webinars, and harnessing the power of digital opinion leaders.  Chris’s expertise lie in identifying the optimal content, delivered in the best format, to enact positive change for the healthcare industry.

Caroline Phillips is Vice President of Medical Affairs at Medscape, with over 25 years of experience in the pharmaceutical industry. Medscape Medical Affairs specialises in the translation of clinical science through effective medical communications to enhance patient care. With a background in pharma, medical publishing and CME, Caroline brings a broad perspective to conversations in medical affairs and a strong desire to optimise effectiveness in medical education, delivering programs that are guaranteed to engage the right HCP targets, with measurable impact. 

Zoë has been providing life sciences consultancy for over 15 years, specialising in early-stage product and portfolio strategy with meaningful patient engagement, facilitating faster, smoother progression of assets from inception to market, maximising value for brands, businesses and patients. Zoë’s career has been varied, including roles at DEFRA and the Human Genome project, obtaining a Master’s Degree in Marine Science and then a PhD in Clinical Neurosciences, before switching to industry.

Stuart Pocock is Professor of Medical Statistics (since 1989) at the London School of Hygiene and Tropical Medicine, a leading European centre of excellence for biostatistical research and teaching.

His primary research interest concerns clinical trials, both as regards methodological developments and applied collaboration in major trials, mainly in cardiology. He also has interests in observational epidemiology especially pharmaco-epidemiology. His particular methodological areas of expertise include: standards for the statistical reporting of trials and epidemiological studies, the statistical ethical and organisational principles for data monitoring including early stopping guidelines, the win ratio approach to a hierarchical composite of outcomes with clinical priorities, adaptive designs, handling non-proportional hazards, the value of repeat-event analyses, use and misuse of propensity scores, the pros and cons of non-inferiority trials, problems of multiplicity in trial reporting, eg, subgroup analyses, multiple outcomes and covariate adjustment, and the development/validation of prognostic risk scores.

Professor Pocock and his colleagues run a statistical centre for the design, conduct, analysis and reporting of major clinical trials, especially in cardiovascular diseases. He is also a consultant statistician for a wider range of clinical trials in which expert statistical advice is needed, and serves as a statistical member of many trial data monitoring and steering committees.

He collaborates internationally especially with the Centro Nacional de Investigaciones Cardiovasculares in Madrid, and the Cardiovascular Research Foundation and Mount Sinai School of Medicine in New York. He is a frequent lecturer on a variety of clinical trials issues, and has published over 600 articles in peer-reviewed journals, and a popular textbook “Clinical Trials: a Practical Approach''.

Sue is no stranger to optimising value!

Having spent the first few years of her career as a UK hospital pharmacist, managing formularies, Sue understands only too well the need to target limited healthcare resource and optimise new drug use. She has never lost this grounding in the realities of healthcare systems and spent 15 years in the global team at AstraZeneca, helping to shape new organisational initiatives, as health technology assessments were an emerging concept, and “global to local” activities became a key driver of a successful brand launch.

Sue now heads up the Evidence and Access team at Prime, with a leadership team spanning the US and Europe, supporting clients across the lifecycle, to make sure that value demonstration and evidence is optimal, not just for launch but far beyond.

Sue is passionate about driving cross-functional working practices and believes that successful market access requires integrating your best strategic thinking early and collaboration without silos – from emerging brands through to launch!

Bélène is a Director of Epidemiology at OXON Epidemiology specialized in the design and conduct of global secondary data studies. Bélène has a PhD in Clinical Epidemiology from the London School of Hygiene & Tropical Medicine (LSHTM) and a Master of Public Health from Imperial College London. Before joining OXON, she was previously a Research Fellow at LSHTM investigating the impact of multimorbidity on surgical outcomes.